Recite me link

1. For the 4-month period from September to December 2020, how many patients has your trust treated with the following anti-VEGF treatments:
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Fluocinolone acetonide
f. Ranibizumab
2. Within your trust how many intra-vitreal injections/implants of each of the following treatments have been used in the four-month period from September to December 2020:
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Fluocinolone
f. Ranibizumab
3. If your trust is able to identify intra-vitreal injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from September to December 2020 for each of the following conditions:
Wet Age Related Macular Degeneration (wAMD)
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Ranibizumab
Diabetic Macular Oedema (DMO)
a. Aflibercept
b. Bevacizumab
c. Dexamethasone
d. Ranibizumab
Retinal Vein Occlusion – Central (CRVO) or Branch (BRVO)
a. Aflibercept
b. Bevacizumab
c. Dexamethasone
d. Ranibizumab

Download response Anti-VEFG treatments for eye conditions. 081221.docx